Quetiapine‑Induced Hyperprolactinemia

Overview

Hyperprolactinemia refers to an abnormally high level of the hormone prolactin in the bloodstream. Prolactin is produced by the pituitary gland and primarily regulates breast development and milk production. While many causes exist (pituitary tumors, hypothyroidism, pregnancy, etc.), certain medications—particularly antipsychotics—can also raise prolactin levels.

Quetiapine (brand name Seroquel) is a second‑generation (atypical) antipsychotic used for schizophrenia, bipolar disorder, major depressive disorder, and off‑label for insomnia or anxiety. Compared with older agents such as risperidone or haloperidol, quetiapine is generally considered “prolactin‑sparing.” However, case reports and pharmacovigilance data show that a subset of patients develop hyperprolactinemia while taking quetiapine, especially at higher doses or when combined with other prolactin‑raising drugs.

• Who it affects: Adults of any gender taking quetiapine; women of reproductive age are more likely to notice symptoms because menstrual changes are obvious.
• Prevalence: Large database studies report prolactin elevation in 3‑10 % of quetiapine users, versus 15‑30 % for typical antipsychotics and 5‑12 % for other atypicals such as olanzapine. The true prevalence may be higher because mild elevation often goes unnoticed.

Understanding the link is essential because untreated hyperprolactinemia can lead to bone loss, infertility, and psychological distress.

Symptoms

Symptoms result from excess prolactin acting on breast tissue, the hypothalamic‑pituitary‑gonadal axis, or central nervous system pathways. Not every patient experiences all symptoms, and some may be asymptomatic with only laboratory abnormalities.

Women

• Amenorrhea or oligomenorrhea: Missed or infrequent periods.
• Galactorrhea: Milky nipple discharge unrelated to pregnancy or breastfeeding.
• Infertility: Difficulty conceiving due to suppressed gonadotropin‑releasing hormone (GnRH) secretion.
• Decreased libido and vaginal dryness.
• Headaches or visual changes: May reflect a pituitary adenoma, which must be ruled out.

Men

• Erectile dysfunction.
• Decreased libido.
• Gynecomastia: Breast enlargement.
• Galactorrhea (rare).
• Infertility due to low testosterone.

Both sexes

• Headaches or visual field cuts (if a pituitary mass is present).
• Bone pain or fractures over time (osteoporosis secondary to low estrogen/testosterone).
• Fatigue, mood swings, or anxiety related to hormonal imbalance.

Causes and Risk Factors

Quetiapine raises prolactin by blocking dopamine D2 receptors in the tuberoinfundibular pathway. Dopamine normally suppresses prolactin secretion; when its action is inhibited, prolactin levels rise.

• High daily dose: Doses >400 mg/day are more likely to interfere with dopamine signaling.
• Rapid dose escalation: Sudden increases give the pituitary less time to adapt.
• Concurrent use of other prolactin‑elevating drugs: Risperidone, haloperidol, certain antidepressants (e.g., SSRIs), metoclopramide.
• Female sex, especially pre‑menopausal: Hormonal milieu makes changes more apparent.
• Pre‑existing pituitary abnormalities: Microadenomas can amplify drug‑induced prolactin spikes.
• Renal or hepatic impairment: Reduced drug clearance increases plasma concentration.

Diagnosis

Diagnosis combines clinical assessment, laboratory testing, and imaging to differentiate drug‑induced hyperprolactinemia from other etiologies.

Step‑by‑step approach

1. History & Physical Examination: Review medication list, menstrual/sexual history, and look for galactorrhea or breast changes.
2. Serum prolactin measurement: Fasting morning sample; values >25 ng/mL (women) or >20 ng/mL (men) are considered elevated. Mild elevations (up to 2–3× upper limit) are common with antipsychotics; >100 ng/mL warrants further evaluation.
3. Rule out physiologic causes: Pregnancy test, thyroid‑stimulating hormone (TSH) level, renal function tests.
4. Imaging (if prolactin >100 ng/mL or persistent after medication change): Magnetic resonance imaging (MRI) of the sellar region to exclude pituitary adenoma.
5. Additional labs (if needed): Sex hormones (estradiol, testosterone), bone density (DEXA) if chronic elevation is suspected.

Reference: Mayo Clinic. “Hyperprolactinemia.” https://www.mayoclinic.org.

Treatment Options

Treatment aims to lower prolactin, resolve symptoms, and maintain control of the underlying psychiatric condition.

1. Medication Adjustments

• Dose reduction: Lowering quetiapine to the minimum effective dose often normalizes prolactin.
• Switching antipsychotics: Transition to a prolactin‑sparing agent (e.g., aripiprazole, brexpiprazole, clozapine) under psychiatric supervision.
• Adjunctive dopamine agonist: Low‑dose cabergoline or bromocriptine can suppress prolactin but may aggravate psychosis; use only with specialist input.

2. Symptomatic Management

• Hormone replacement therapy (HRT): For women with hypoestrogenism or men with low testosterone, after endocrine evaluation.
• Bone health support: Calcium + vitamin D supplementation, weight‑bearing exercise, or bisphosphonates if DEXA shows osteoporosis.

3. Lifestyle Interventions

• Maintain a balanced diet rich in calcium and vitamin D.
• Engage in regular aerobic and resistance exercise (150 min/week).
• Avoid smoking and limit alcohol, both of which worsen bone density.

4. When Surgery is Needed

Only if a prolactin‑secreting pituitary adenoma (prolactinoma) is identified and does not respond to medical therapy. Trans‑sphenoidal surgery is the standard approach.

Living with Quetiapine‑Induced Hyperprolactinemia

Patients can lead normal lives with appropriate monitoring and self‑care.

• Regular lab checks: Serum prolactin every 3–6 months after any medication change.
• Track menstrual/sexual symptoms: Use a simple diary to note period regularity, breast discharge, libido changes.
• Bone health monitoring: Baseline DEXA at diagnosis; repeat every 2–3 years.
• Communicate with your care team: Keep your psychiatrist, primary care physician, and, when needed, an endocrinologist in the loop.
• Stress management: Mindfulness, yoga, or counseling can alleviate anxiety that sometimes accompanies hormonal symptoms.

Prevention

Preventive strategies focus on minimizing risk before hyperprolactinemia develops.

• Choose the lowest effective quetiapine dose; avoid unnecessary dose escalations.
• Screen baseline prolactin and menstrual/sexual function before starting therapy.
• Prefer prolactin‑sparing antipsychotics when a patient has a history of endocrine issues.
• Educate patients about early signs (e.g., breast discharge, menstrual changes) so they can report promptly.
• Manage comorbidities (hypothyroidism, renal disease) that can exacerbate prolactin rise.

Complications

If left untreated, chronic hyperprolactinemia can lead to serious health problems.

• Infertility: Persistent gonadotropin suppression reduces ovulation or spermatogenesis.
• Osteoporosis & fractures: Estrogen or testosterone deficiency accelerates bone loss—a CDC study links prolonged hyperprolactinemia to a 1.7‑fold increase in hip fracture risk.
• Psychological impact: Body image concerns, depressive symptoms, or sexual dysfunction may worsen underlying psychiatric illness.
• Pituitary macroadenoma: Rarely, long‑standing stimulation can lead to tumor growth, causing visual field defects.

When to Seek Emergency Care

**Sources:** Mayo Clinic, CDC, NIH (National Institute of Mental Health), WHO, Cleveland Clinic, “Antipsychotic‑induced hyperprolactinemia: A systematic review” (J Clin Psychopharmacol, 2022), and FDA Adverse Event Reporting System (FAERS) data.